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ABSTRACT
canSAR is a fully integrated cancer research and
drug discovery resource developed to utilize the
growing publicly available biological annotation,
chemical screening, RNA interference screening, ex-
pression, amplification and 3D structural data.
Scientists can, in a single place, rapidly identify bio-
logical annotation of a target, its structural charac-
terization, expression levels and protein interaction
data, as well as suitable cell lines for experiments,
potential tool compounds and similarity to known
drug targets. canSAR has, from the outset, been
completely use-case driven which has dramatically
influenced the design of the back-end and the func-
tionality provided through the interfaces. The Web
interface at http://cansar.icr.ac.uk provides flexible,
multipoint entry into canSAR. This allows easy
access to the multidisciplinary data within, including
target and compound synopses, bioactivity views
and expert tools for chemogenomic, expression and
protein interaction network data.
INTRODUCTION
Advances in large-scale genomics technologies have trans-
formed the drug discovery ﬁeld by providing unparalleled
biological and pharmacological information about poten-
tial disease causing genes. Cancer research in particular
beneﬁts from these advances as it is often caused by com-
plex genetic events that may not become obvious without
large-scale, systematic analysis of multi-genome heteroge-
neous data (1,2). However, scientists can rarely make use
of the full breadth and depth of relevant data that are
often available. The difﬁculty of obtaining, effectively
integrating and maintaining such large sets of heteroge-
neous data such as genomics, cellular biology, medicinal
chemistry and structural biology is the chief factor (3).
Furthermore, the majority of public resources available
tend to be domain speciﬁc resulting in researchers either
making their decisions based on narrow or incomplete
data contexts, or spending weeks at a time compiling data
relating to their query from different sources. A growing
number of resources exist that attempt to bring together
such heterogeneous data [e.g. iHop (4) and GeneCards
(5)]; however, most simply provide compilations of data
through a web interface. While they can be a useful quick
look-up, most of these resources do little or no actual in-
tegration of the data; instead the meta-data are provided
in large dumps through a web interface and require the
user to trawl through long pages of listed information.
Some resources are notable for better integration and us-
ability such as cancerResource (6), that provides excellent
query and integration of gene expression data linked to
biological annotation of targets and cellular chemical
screening data, with powerful expression data query tools;
but by design, excludes other data sources that may well
be relevant in broader cancer translational research.
Moreover, chemical activity data and search capabilities
are limited, as are query mechanisms. On the other hand,
the ChEMBL database (7), which is a large curated and
linked database of bioactive compounds, their biological
targets and pharmacological data, across multidisciplines,
has powerful chemical search and clustering tools and ex-
tensive bioactivity data, but is not designed to be cancer
speciﬁc and thus does not include extensive, biological
data relevant to oncology such as cancer gene expression
and ampliﬁcation data.
What was required is a resource that integrates data at a
very large scale, which captures cancer-relevant biological
data such as expression, ampliﬁcation, RNAi etc, together
with large protein–protein interaction data, chemical
screening and pharmacological activities and 3D struc-
tures. Furthermore, to maximize beneﬁts from integration
of these vast heterogeneous data sets, the user needs to be
presented with meta-data that is logically organized and
linked in a way that mimics real life uses and workﬂows.
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For example, it would be extremely valuable to enable
obtaining integrated information about expression, muta-
tion and functional annotation for a target together with
its druggability, identify suitable cellular models for drug
testing, identify chemical tool compounds and understand
the wider context of the likely action of these compounds
on the target’s pathway neighbours, all within one place,
and without extensive expertise in computational tech-
niques, medicinal chemistry and genomics.
Such integration requires smart underlying technical
data modelling, data cross-referencing and redundancy
elimination, as well as regular and reliable update pro-
cesses. canSAR addresses these needs by integrating data
from a plethora of domains and providing a use-case
driven web-based interface to help answer translational
research questions.
Database design and processing pipeline
The design and implementation of canSAR has been
entirely use-case driven. canSAR was designed in a
modular manner such that the modelling and inclusion of
new data types in the future [e.g. clinical outcome or drug
metabolism and pharmacokinetics (DMPK) data] is rela-
tively easy. This provides the ability and support to
expand the functionality and usefulness of canSAR as
new requirements are found. The data model is designed
around elemental and association data types. Elemental
types (e.g. molecular target, compound, cell) represent
the core components of the system. These elements can
then be associated via different association types, e.g. a
compound and a molecular target can be associated via
a ‘screening’ association, a ‘drug action’ association, or a
‘3D-structural complex’ association. The associations in
turn are then linked to the experimental data, sources of
origin and publication references where relevant. These
generic key data types provide the ﬂexibility described
above. Figure 1 shows an illustration of this modular
design with the core elemental data types represented as
large jigsaw pieces and the association data as the inter-
connecting pieces. Using this paradigm, new associations
Figure 1. Modular design of canSAR: large pieces represent elemental types, small pieces represent associations. This design allows new elemental
data types to be added and new interconnecting (association) data to be introduced.
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between any of the key data types can be provided for
easily.
Data sources from collaborators are mirrored to ensure
that canSAR is up-to-date. In order to process these exter-
nal sources into a format suitable for integration into
canSAR, a suite of pipelines have been created which
allows the seamless integration of new data from existing
sources, and most importantly, check for uniqueness
among the different data sources. A fraction of the data
within canSAR is duplicated in several data sources and it
is imperative that this redundancy is recorded and that the
useful information for each duplicate is extracted. In some
cases, this is reasonably trivial, but in others (compounds
and molecular targets are good example), accurate and
appropriate tests for uniqueness and data storage are
challenging. Most of the data pipelines involved the fol-
lowing steps: acquisitions of local copy, pre-processing
into suitable format, uniqueness testing of existing data,
loading of data into canSAR and rebuilding of data
source logs. Some of the data sources are updated monthly,
however some are updated more frequently or at variable
intervals. Each of the speciﬁc pipelines is adapted to suit
the needs of the speciﬁc data source. Where possible and
appropriate, a source’s API is utilized through the use of
simple REST or SOAP services. This has the beneﬁt of
ensuring that the data are as up-to-date as possible and
removes steps of mirroring and integrating.
To ensure long-term growth and utility, canSAR
provides ﬂexibility for new data and data types.
Providing the centralization and ability to rapidly interro-
gate such disparate data is of immediate beneﬁt to users
who can now access data in seconds that would have taken
days or weeks to compile. Figure 2 illustrates some
common information requests taken into consideration
in the design of canSAR.
Data content
canSAR contains data pertaining to the entire human
proteome as represented by UniProt (8) human sequences
and RefSeq (9) human transcriptome. Additionally, a
large number of model organism proteins are included
where useful data are available for them. Family annota-
tion from Pfam (10) or manual curation by the canSAR
team is provided. Predicted secretion signals, transmem-
brane regions and secondary structures are calculated
using standard methods [SignalP (11), TMHMM (12)
and PSIPRED (13)].
Currently, canSAR contains data from four publicly
available chemical screening data sources. The most ex-
pansive is ChEMBL, which contains 5.4 million activities
from 42 500 different publications (correct as of August
2011) and is updated approximately once a month. The
next largest data set is the NCI-60 panel of 60 diverse
human cancer cell lines screened against more than
100 000 compounds and natural products (14). This cur-
rently supplies canSAR with 2 663 013 activities. Other
sources include Binding DB (15) (620 198 activities) and
the Genomics of Drug Sensitivity project (8498 activities).
Compound structures obtained from the resources men-
tioned above, or manually entered by the canSAR team
(e.g. some clinical candidates), are all assessed, standard-
ized and registered against a strict pipeline that handles
chemical duplicates, identiﬁes alternative salt forms and
stereoisomers. The compounds are stored in the database
using the Accelrys Direct chemical cartridge for Oracle to
allow compound searching. A large set of descriptors is
calculated for each of the compounds including molecular
weight, polar surface area, number of hydrogen-bond
donors and acceptors and whether they contain toxico-
phores or reactive groups (16). To enable clustering of
Figure 2. Common requested information in cancer translational research used to design the user interface. Query can be from a biological or
chemical starting point. Users often require complex, interconnected but concise information. The data reports generated in canSAR are used to
underpin subsequent discussions and the design of the next experiment.
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compounds into chemically related groups, the Bemis and
Murcko (17) frameworks are calculated for all
compounds.
Publicly available gene expression data are currently
obtained from NCI-60 DTP Human Tumour Cell Line
Screen (18), The Cancer Genome Atlas (TCGA) and
ArrayExpress (19). While the NCI-60 and TCGA data
has been processed and integrated into canSAR the
ArrayExpress data are obtained live via web services.
Further annotation for cell lines and gene expression
microarray probes is obtained and integrated from
COSMIC (20), ATCC and speciﬁc platform providers
(Affymetrix and Agilent).
Large volume data repositories for RNAi data are not
commonplace; hence, most of the RNAi data in canSAR
are extracted manually from choice publications and web
resources [e.g. (1,21,22,23)]. Increasingly, data is provided
through sources such as the Broad Institute (http://www
.broadinstitute.org//scientiﬁc-community/data) and such
data will be added in the future from as many sources
and collaborators as possible in order to bolster the con-
ﬁdence in any ﬁndings.
Gene copy number data have been obtained and integ-
rated from the copy number variation (CNV) Project
(24,25). Currently, this makes up 1.4 billion copy number
data points for 747 cell lines.
canSAR is useful because it brings together in one place
all these diverse data. It is important at this point to
remind readers that these data, as with any published data,
are useful for hypothesis generation-speciﬁc measurements
and endpoints need to be veriﬁed experimentally.
To tackle the large variety of sources of protein inter-
action data, we began by collaborating with two providers
of compiled curated interaction data, namely STRING
(26) and ROCK (27). Their APIs are utilized to obtain
data while maintaining the beneﬁt of the efforts invested
by these providers in annotation and conﬁdence curation.
Future plans for canSAR include better utilization of
PSICQUIC (28) and more extensive collaboration with
resources such as IntAct (29) and Reactome (30). These
data sources are all valuable sources of annotated protein–
protein interactions. They have different strengths and
focuses, e.g. STRING has a visually striking structural
annotation paradigm, and IntAct and ROCK have exten-
sive links for each node through their tabular representa-
tions or though invoking options within Cytoscape. For
detailed network analysis, such resources are very
powerful. However, there is additionally a need to instantly
annotate an interaction network by druggability, chemical
screening, RNAi screening as well as structural annota-
tion to highlight possible intervention points instantly.
We aim to achieve this within canSAR (see case studies
below)
The primary source for canSAR structural data is the
RCSB PDB (31). Data from PDBe (32) helps maintain an
up-to-date mapping between various databases such as
UniProt (8), Pfam(10) protein family repository, SCOP
structure classiﬁcation database (33) and provides infor-
mation in computationally parseable ﬁles. Ligand infor-
mation is also gathered from PDBe in the form of
PDBeChem. Domain speciﬁc information is gathered from
SCOP and Astral (34). A number of structural descriptors
are calculated for all structures using DSSP (35), Ligplot
(36) and HBPlus (37), providing assignment of secondary
structures, dihedral angles and interaction maps.
The approved drugs from the FDA are captured (re-
gardless of therapeutic indication) and their efﬁcacy targets
were expert-curated from published literature (38). As well
as providing this useful annotation, it is possible to infer
druggability by precedence through the presentation of the
sequence similarity to the existing targets of launched
therapeutics (39). A continuing effort is being carried
out by the canSAR team to manually curate cancer clinical
candidates from clinical trial and company progress
reports.
Full up-to-date release notes are available on the
canSAR interface. A snap shot of the release notes from
August 2011 can be found in the Supplementary Data.
Web visualization
While canSAR integrates an unprecedented set of transla-
tional research data, its major unique advantage is the
presentation and interrogation tools. canSAR is available
via http://cansar.icr.ac.uk. Users can obtain logical and
concise summaries of broad state-of-the-art knowledge
without being overwhelmed by pages of concatenated
data. The interface provides biological annotation, gene
expression, disease association, structural and pharma-
cological data, and produces graphical and tabular
summary reports pertaining to any aspect of these data.
Additionally, wider ranging and more expert-style ques-
tions can be asked of the data using the expert and batch
query tools. The interface development is driven by typical
use-cases in cancer translational research, drug discovery
and chemical biology and caters for users from different
backgrounds (biology, chemistry, clinical etc).
Example entry points include target/cell line/compound
keyword searches, sequence similarity searches, compound
structure searches and the facility to upload lists of iden-
tiﬁers as a query. Expert tools allow retrieval of extensive
chemogenomic annotations, polypharmacology maps,
compound selectivity and bioactivity proﬁles, expression
details and pathway enrichment analysis.
Almost all canSAR functionality is available without the
need for registration. However, a simple user registration
facility is available to enable running large batch searches
(emails are sent when batch analysis is ready to view),
saving favourite complex searches, data alerts or setting
up regularly used ﬁlters etc.
Data export and sharing
Users often wish to export speciﬁc analysis results
obtained from the interface. In most sections of
canSAR, users are able to export the current results in
various formats including Excel, tab-delimited text, SDF
and MIABE (40) compliant XML. Detailed examples of
the web interfaces usage can be found in the Case Studies
section.
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Database and web implementation
canSAR is running on an Apache web server implemented
in PHP, Javascript, Perl and Java. The data reside in an
Oracle 11g database. Chemical compound search and
handling is supported by the Accelrys direct cartridge.
The data processing pipelines are written in Perl, Python
and Java and utilize Openbabel, CDK (41) and Pipeline
Pilot (Accelrys Inc).
CASE STUDIES USING CANSAR
canSAR has been well documented with quick start guides
and detailed case studies. Below are some example use
cases addressing the major functionality.
Obtain state of knowledge about a target
canSAR provides target synopses, which present categor-
ized summaries of the knowledge that is available for each
target. This synopsis is usually the ﬁrst point of access for
a user with a given target in mind. These summaries are
divided into structural annotation, drug and clinical can-
didates, structural and ligand-based druggability, screen-
ing and chemistry, RNAi studies, pathway, cell line and
tissue expression, ampliﬁcation and interaction networks.
Figure 3A shows a target synopsis with the gene ex-
pression section selected and known drugs (Figure 3B).
Figure 3C shows a hierarchical disease tree with expres-
sion annotations obtained through ArrayExpress. A user
can navigate to other areas of canSAR from many of the
sections within the synopsis. Target synopsis can be
accessed from any target search results page.
Identifying potential tool compounds for a target of
interest
If a target has—itself—been chemically screened, the
bioactive compounds are summarized and can be
obtained via the target synopsis described above.
However, if a target is not itself screened, or if a
wider selection of compounds is required, likely active
compounds can be obtained via homology searches.
Figure 4A shows the results of a sequence similarity
Figure 3. View of some components of target synopsis for Epithelial Growth Factor Receptor (EGFR). The main panel (A) shows gene expression
ordered by the highest expressed probeset from the NCI60 cell line panel expression data. The details of all available probesets can be seen in the
expander. At the top of the main panel is the target synopsis banner, which is made up of icons that indicate certain properties. From the left, these
properties are: structure availability, drug target status, RNAi data availability, enzyme status and mutation data availability. Approved drugs are
shown in (B). If the drug is an antibody, then a generic antibody icon is displayed. If the drug is a small molecule then a link to the compound
synopsis is provided. Panel (C) shows tissue sample expression data from ArrayExpress hierarchically classiﬁed into cancer types.
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search resulting in a number of homologous targets with
screening data. The bioactivity data are ﬁltered
to obtain the most active compounds (Figure 4B) and
the resulting compounds can be viewed and exported
(Figure 4C). In the selection of a tool compound,
as well as level of activity, molecular diversity and like-
ly cross-reactivity are taken into account. Molecular di-
versity can be obtained from the Bemis and
Murcko frameworks, and cross reactivity can be
visualized using the compound bioactivity proﬁle plots
(Figure 4D)
Identifying potential druggable intervention points from
a protein interaction network annotated with chemical
and biological data
A common problem encountered in drug discovery is iden-
tifying likely chemical intervention points in a pathway or
Figure 4. Identiﬁcation of tool compounds for ABL1. Panel (A) shows the search results from a sequence similarity search of ABL1. Only homo-
logues with percentage identities >50% are selected to increase the chance of ﬁnding an active against ABL1 itself. Panel (B) shows the chemical
space of good afﬁnity compounds against ABL1 and selected homologues. Panel (C) displays only sub micromolar afﬁnity compound structures. A
search instigated using these compounds allows identiﬁcation of likely selectivity across homologues. Panel (D) shows the bioactivity proﬁle of these
compounds. Compound identiﬁers are on the y-axis and target names on the x-axis. A blue dot represents a measured compound bioactivity and the
darker the dot the higher the afﬁnity of the compound against the target. This proﬁle can be used to indicate the selectivity of the compounds against
measured targets.
D952 Nucleic Acids Research, 2012, Vol. 40, Database issue
interaction network of biological relevance. canSAR
provides chemical and biological annotation of protein
interaction networks, allowing rapid identiﬁcation of
highly characterized or druggable points on the network
(Figure 5). This is achieved by mapping a summary of the
annotation within canSAR onto each node in the network,
thus highlighting druggable and chemically and genetical-
ly screened targets. Moreover, through the integration in
canSAR, the user can instantly access chemical screening
data, launched drugs, structural annotation and other fea-
tures of the protein at the click of a button directly from
the interaction network. A further utility for this feature
is the ability to identify alternative intervention points
for an undruggable target. This annotated network can
be obtained via a target synopsis, or through a batch
search in the chemogenomic annotation tool. Using this
network, a user is able to identify whether any closely
interacting proteins are predicted as druggable by both
structural and ligand-based techniques. Users are able to
expand and remove individual nodes to manipulate the
network, and then inspect all chemical and screening
data for the entire network.
Identify published 3D binding modes for a compound
Compounds in canSAR can be retrieved by performing
keyword or chemical structure searches; alternatively they
can be obtained via their activity through a biological
Figure 5. A screenshot of an annotated interaction network for ABL1. Each node is a protein coloured by the presence/absence of certain types of
data. Each protein is annotated with chemical and biological information as indicated by the activation of the trafﬁc lights. From the left, these
trafﬁc lights are green if the following data is positively available: chemical screening data (informs user of previous screening efforts against target),
good afﬁnity chemical screening data (tool compounds available), drug target status (green of target is the target of an approved pharmaceutical),
enzyme status (green if the protein is an enzyme, as enzymes form 50% of successful drug targets (38) and enzymatic activity is useful for assay
development during target validation), structural characterization, RNAi data and structure-based and ligand-based druggability. The colour of the
node is then determined from the number of different annotation types available.
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search. Understanding likely binding modes for a
compound, and whether there is evidence for them, is an
important part of understanding mechanisms of com-
pound effects and is very valuable in lead optimization.
In this example, the drug imatinib is identiﬁed through a
chemical search. Imatinib is known to bind to ABL1, but
has subsequently been found to bind to a wider range of
kinases. Bioactivities of imatinib against molecular targets
or cell lines, together with any ADMET (Absorption,
Distribution, Metabolism, Excretion and Toxicity) data
available are summarized in the Compound Synopsis
(Figure 6A). This page also allows obtaining these bio-
activity data for a compound’s (in this case, imatinib) ana-
logues. If a compound has been solved in complex in one
or more 3D structures, a link from this page leads to
the list of all 3D structures containing this compound.
This allows identiﬁcation of valuable 3D data for the com-
pound in any system in which it has been characterized,
regardless of protein family or organism, as shown here
for imatinib. Furthermore, the effective integration of
structure comparison and ligand interaction maps allows
comparison of binding modes for the compound. In this
case, the structure of imatinib has been solved in complex
with a wide variety of protein kinases (Figure 6B).
Selecting any set of structures allows viewing structural
superposition. Here, the structure of imatinib in complex
with ABL1 and with Spleen Tyrosine Kinase (SYK) (42)
are compared (Figure 6C). The superposition shows the
alternative binding modes that imatinib adopts within the
two kinases. Users can access a graph showing the RMS
over the whole sequence and interact with this graph to
highlight the areas of the superposition that have the most
mobility.
Additional example batch mode use cases are described
in the Supplementary Data.
CONCLUSIONS
Here, we have presented the canSAR database and web
interface for the integration of heterogeneous data for
Figure 6. Use case for imatinib. The main panel (A) shows the compound synopsis for imatinib. The structure is shown with the murko scaffold
highlighted in red. The banner at the top highlights certain properties indicated by icons which are active/inactive. From the left, the icons are active
if the following properties are positive: is chiral, is rule-of ﬁve compliant, is solved in complex in a 3D structure, contains a toxicophore, is a clinical
candidate, is a marketed drug, has a black-box warning, is oral, is injected, is topical and is a prodrug. Panel (B) displays the 3D structures solved in
complex with Imatinib. Panel (C) shows the superposition of a SYK structure with an ABL1 structure. In green is the well-known DFG-out binding
mode. In yellow is the alternative mode adopted in SYK when imatinib changes conformation and binds in a canonical, directly ATP competitive
mode.
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cancer translational research and drug discovery and the
provision of these data through a ﬂexible user interface.
canSAR’s aim is to aid informed hypothesis generation
and cancer translational research by a more comprehen-
sive, yet concise, view of relevant data, and enabling
powerful interrogation and reporting tools. canSAR
contains large amounts of data from a variety of sources
including chemical screening, gene expression, RNA inter-
ference, genomic variation, protein–protein interaction
and 3D structural data. A user-driven web interface has
been designed and implemented to provide tailored entry
methods, and allow logical exploration and interrogation
of data within canSAR. The interface allows users to
obtain answers to common cancer research questions,
such as rapidly obtaining biological and chemical annota-
tion together with druggability considerations, explore
genomic variation and gene-expression data, identify rele-
vant cell lines for experiments, and tool compounds for
analysis. Throughout the various levels of the interface,
data can be exported in a variety of manners including
Excel, SDF and MIABE XML. Also, if registered, user
speciﬁc work spaces are available which save searches,
ﬁlters and allow larger batch queries to be run.
Over the next year, canSAR will be expanded to
contain a much larger body of biological data particularly
gene expression and RNAi screening data and ex-
panded annotation of clinical samples and cell lines.
Additionally, in collaboration with protein–protein inter-
action data providers listed above, we aim to integrate
directionality data into the network diagrams wherever
possible.
Integrating masses of publicly available information in
a consistent and up-to-date manner, canSAR is the largest
integrated cancer research and drug discovery resource
freely available. The efforts that an individual researcher
would have to undertake to collect and process similar
amounts of data sources for information on a given
target, cell line or compound of interest cannot be over-
stated. canSAR removes this arduous and time-consuming
step of data collection and processing and provides an
intuitive centralized repository of data, allowing research-
ers to focus more quickly on speciﬁc areas of interest, or to
eliminate potentially time consuming leads early on. Using
canSAR, these types of decisions can be better informed
and can be made after having taken the whole background
of a target into account.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1 and 2.
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